2017
Jensen IS , Wu E, Sacks N , Cyr P , Chung K. 2017. Budget impact analysis of CPX-351 in the treatment of patients with treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC) from a US payer perspective. Blood 130(Sup 1):5615; 10.1182/blood.V130.Suppl_1.5615.5615 .
View Abstract
Publication: Abstracts and Presentations
Meddings J, Reichert H , Green MT, Safdar N, Krein SL, Olmsted RN, Watson SR, Edson B, et al. 2017. Evaluation of the association between catheter‐associated infections and measures of safety culture: Results of two national collaboratives. BMJ Qual Saf 26(3):226-235; doi: 10.1136/bmjqs-2015-005012 . PMID: 27222593.
View Abstract
Publication: Manuscripts
Friedman D, Fryzek J, Jiang X , Bloomfield A, Ambrose CS, Wong PC. 2017. Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses. PLoS One 12(3):e0172512; doi: 10.1371/journal.pone.0172512 . PMID: 28253361.
View Abstract
Publication: Manuscripts
Pastula ST , Hackett J, Coalson J, Jiang X , Villafana T, Fryzek J. 2017. Hospitalizations for respiratory syncytial virus disease among adults in the United States, 1997 to 2012. Open Forum Infect Dis 4(1):ofw270; doi: 10.1093/ofid/ofw270 . PMID: 28480262.
View Abstract
Publication: Manuscripts
2016
Nicholson G, Gandra SR, Halbert RJ, Richhariya A, Nordyke RJ . 2016. Patient-level costs of major cardiovascular conditions: A review of the international literature. Clinicoecon Outcomes Res 21(8):495-506; doi: 10.2147/CEOR.S89331 . PMID: 27703385.
View Abstract
Publication: Manuscripts
Jensen I , Zacherle E, Blanchette C, Zhang J, Yin W. 2016. Evaluating cost benefits of combination therapies for advanced melanoma. Drugs Context 5:212297; doi: 10.7573/dic.212297 .
View Abstract
Publication: Manuscripts
Sacks NC , Noone J, Cyr PL , Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.
Publication: Abstracts and Presentations
Jensen IS , Wu C, Fan W, Lodise T, Nicolau, DP, DuFour S, Cyr PL , et al. 2016. Use of oritivancin in moderate-severe ABSSSI patients requiring IV antibiotics: US hospital budget impact analysis. J Manag Care Spec Pharm 22(6):752-64; doi: 10.18553/jmcp.2016.22.6.752 .
View Abstract
Publication: Manuscripts
Jensen IS , Lodise TP, Fan W, Wu C, Cyr PL , Nicolau DP, DuFour S, et al. 2016. Use of oritavancin in acute bacterial skin and skin structure infection patients receiving intravenous antibiotics: A US hospital budget impact analysis. Clin Drug Investig. 2016 36(2):157-68; doi: 10.1007/s40261-015-0365-8 .
View Abstract